title: Oritavancin for acute bacterial skin and skin structure infections.
abstract: BACKGROUND
  Inpatient treatment of acute bacterial skin and skin structure infections (ABSSSIs) exerts a significant economic burden on the healthcare system. Oritavancin is a concentration-dependent, rapid bactericidal agent approved for the treatment of ABSSSIs. Its prolonged half-life with one-time intravenous (i.v.) dosing offers a potential solution to this burden. In addition, oritavancin represents an alternative therapy for Streptococci and multidrug-resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. Animal models have also shown promising results with oritavancin for other disease states including those that require long courses of i.v.
  
  
  METHODS
  
  
  
  METHODS
  This review covers oritavancin's basic chemistry, spectrum of activity, pharmacodynamics/pharmacokinetics and efficacy in clinical trials, and provides expert opinion on future directions. To compose this review, a search of PubMed was performed, and articles written in the English language were selected based on full text availability.
  
  
  CONCLUSIONS
  If oritavancin is proven to be a cost-effective strategy for outpatient treatment and prevents complications of prolonged i.v. therapy, it will be sought as an alternative antibiotic therapy for ABSSSIs. In addition, further clinical data demonstrating efficacy in Gram-positive infections requiring prolonged therapy such as endocarditis and osteomyelitis could support oritavancin's success in the current market.
authors: Infectious Disease Fellow, Duke University, Department of Medicine , Durham, NC , USA.
authors: Julia A
authors: JA
authors: Messina
authors: Vance G
authors: VG
authors: Fowler
authors: G Ralph
authors: GR
authors: Corey
mesh_terms: D000208:Acute Disease; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002481:Cellulitis / Q000188:drug therapy / Q000382:microbiology; D002986:Clinical Trials as Topic; D024901:Drug Resistance, Multiple, Bacterial; D006020:Glycopeptides / Q000494:pharmacology / Q000627:therapeutic use*; D006207:Half-Life; D000077427:Lipoglycopeptides; D017192:Skin Diseases, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D014946:Wound Infection / Q000188:drug therapy / Q000382:microbiology; D014640:Vancomycin / Q000031:analogs & derivatives
chemical_list: D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; C100708:oritavancin; D014640:Vancomycin
keywords: Staphylococcus aureus; acute bacterial skin and skin structure infection; lipoglycopeptide; oritavancin